Sign In
Buy TENX
$17.55
-0.770 (-4.20%)
At Close: Jul 10, 2026
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead
02:11pm, Monday, 06'th Jul 2026
Tenax Therapeutics, Inc. is downgraded from Buy to Hold ahead of a major August 2026 phase 3 data readout for TNX-103 in PH-HFpEF. TNX-103 targets a large, unmet market with no approved therapies, but
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd Jul 2026
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
07:00am, Thursday, 02'nd Jul 2026
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax T
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Tuesday, 12'th May 2026
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthene
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th May 2026
CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
07:00am, Monday, 04'th May 2026
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience Mr. Healey is a seasoned pharmaceutical executive with a strong track record
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
07:00am, Wednesday, 22'nd Apr 2026
Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
01:59am, Thursday, 02'nd Apr 2026
Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $10.78 and trad
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
02:37am, Wednesday, 25'th Mar 2026
Shares of Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $10.43 and traded as h
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
07:00am, Tuesday, 10'th Mar 2026
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients
Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)
02:06am, Monday, 09'th Mar 2026
Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the t
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
07:00am, Tuesday, 03'rd Mar 2026
CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutica
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
07:00am, Wednesday, 04'th Feb 2026
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical
Tenax Therapeutics: A Speculative Buy
01:51am, Friday, 09'th Jan 2026
Tenax Therapeutics is a speculative BUY, driven by the commercial potential of levosimendan for PH-HFpEF and a favorable risk/reward profile. Levosimendan's Phase III trial remains well powered, but t
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
01:19pm, Monday, 05'th Jan 2026
Tenax Therapeutics (TENX) initiated with a Buy rating and a $25 price target, implying 127% upside based on DCF analysis. TNX-103, targeting PH-HFpEF, shows a high probability of Phase 3 success with
